All Updates

All Updates

icon
Filter
Product updates
Natera introduces new feature for Prospera heart test for transplant patients
Precision Medicine
Jun 17, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 17, 2024

Natera introduces new feature for Prospera heart test for transplant patients

Product updates

  • Natera has introduced new features to its Prospera Heart test, aimed at improving the detection of rejection in heart transplant patients. The newest features of the test leverages the novel Donor Quantity Score (DQS) technique. DQS is a new metric that normalizes for the background total cfDNA, enhancing donor-derived cell-free DNA (dd-cfDNA) tests for more accurate risk assessment in transplant rejection cases.

  • DQS is combined with the traditional donor fraction in a two-threshold algorithm, providing a single risk analysis result for antibody-mediated rejection (AMR) and acute cellular rejection (ACR). The company claims this feature will help avoid unnecessary biopsies and follow-up procedures.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.